Literature DB >> 18845829

Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.

Yun-Zhou Yu1, Na Li, Rui-Lin Wang, Heng-Qi Zhu, Shuang Wang, Wei-Yuan Yu, Zhi-Wei Sun.   

Abstract

A new gene encoding the Hc domain of Clostridium botulinum neurotoxin serotype F (FHc) was designed and completely synthesized with oligonucleotides. A soluble recombinant Hc of C. botulinum neurotoxin serotype F was highly expressed in Escherichia coli with this synthetic FHc gene. Subsequently, the purified FHc was used to vaccinate mice and evaluate their survival against challenge with active botulinum neurotoxin serotype F (BoNT/F). After the administration of FHc protein mixed with Freund adjuvant via the subcutaneous route, a strong protective immune response was elicited in the vaccinated mice. Mice that were given two or three vaccinations with a dosage of 1 or 10 microg of FHc were completely protected against an intraperitoneal administration of 20,000 50% lethal doses (LD50) of BoNT/F. The BoNT/F neutralization assay showed that the sera from these vaccinated mice contained high titers of protective antibodies. Furthermore, mice were vaccinated once, twice, or three times at four different dosages of FHc using Alhydrogel (Sigma) adjuvant via the intramuscular route and subsequently challenged with 20,000 LD50 of neurotoxin serotype F. A dose response was observed in both the antibody titer and the protective efficacy with increasing dosage of FHc and number of vaccinations. Mice that received one injection of 5 microg or two injections of >or=0.04 microg of FHc were completely protected. These findings suggest that the recombinant FHc expressed in E. coli is efficacious in protecting mice against challenge with BoNT/F and that the recombinant FHc subunit vaccine may be useful in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845829      PMCID: PMC2593168          DOI: 10.1128/CVI.00239-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  23 in total

1.  Comparative immunogenicity of two bivalent botulinum vaccines.

Authors:  A T Brown; A R Gregory; T M Ellis; M N Hearnden
Journal:  Aust Vet J       Date:  1999-06       Impact factor: 1.281

2.  Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin.

Authors:  J L Holley; M Elmore; M Mauchline; N Minton; R W Titball
Journal:  Vaccine       Date:  2000-09-15       Impact factor: 3.641

3.  DNA vaccination protects against botulinum neurotoxin type F.

Authors:  Alice M Bennett; Stuart D Perkins; Jane L Holley
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

Review 4.  Botulinum and tetanus neurotoxins: structure, function and therapeutic utility.

Authors:  Kathryn Turton; John A Chaddock; K Ravi Acharya
Journal:  Trends Biochem Sci       Date:  2002-11       Impact factor: 13.807

5.  Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.

Authors:  M P Byrne; R W Titball; J Holley; L A Smith
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

6.  Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice.

Authors:  L A Woodward; H Arimitsu; R Hirst; K Oguma
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

Review 7.  Development of vaccines for prevention of botulism.

Authors:  M P Byrne; L A Smith
Journal:  Biochimie       Date:  2000 Sep-Oct       Impact factor: 4.079

8.  Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris.

Authors:  Scott K Johnson; Wenhui Zhang; Leonard A Smith; Karen J Hywood-Potter; S Todd Swanson; Vicki L Schlegel; Michael M Meagher
Journal:  Protein Expr Purif       Date:  2003-11       Impact factor: 1.650

9.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

10.  Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies.

Authors:  Mahmood Tavallaie; Alexandre Chenal; Daniel Gillet; Yannik Pereira; Maria Manich; Maryse Gibert; Stephanie Raffestin; Michel R Popoff; Jean Christophe Marvaud
Journal:  FEBS Lett       Date:  2004-08-13       Impact factor: 4.124

View more
  5 in total

1.  Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.

Authors:  Dan-Yang Shi; Fu-Jia Liu; Yun-Yun Mao; Rong-Tian Cui; Jian-Sheng Lu; Yun-Zhou Yu; Xiao-Jie Dong; Zhi-Xin Yang; Zhi-Wei Sun; Xiao-Bin Pang
Journal:  Hum Vaccin Immunother       Date:  2019-07-26       Impact factor: 3.452

2.  Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.

Authors:  Dan-Yang Shi; Bo-Yang Chen; Yun-Yun Mao; Guo Zhou; Jian-Sheng Lu; Yun-Zhou Yu; Xiao-Wei Zhou; Zhi-Wei Sun
Journal:  Hum Vaccin Immunother       Date:  2018-12-04       Impact factor: 3.452

3.  The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo.

Authors:  Alon Ben David; Eran Diamant; Ada Barnea; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Clin Vaccine Immunol       Date:  2013-06-12

4.  Functional EL-HN Fragment as a Potent Candidate Vaccine for the Prevention of Botulinum Neurotoxin Serotype E.

Authors:  Zhen Li; Jiansheng Lu; Xiao Tan; Rong Wang; Qing Xu; Yunzhou Yu; Zhixin Yang
Journal:  Toxins (Basel)       Date:  2022-02-11       Impact factor: 4.546

5.  Development and evaluation of a tetravalent botulinum vaccine.

Authors:  Dan-Yang Shi; Fu-Jia Liu; Zhi-Ying Li; Yun-Yun Mao; Jian-Sheng Lu; Rong Wang; Xiao-Bin Pang; Yun-Zhou Yu; Zhi-Xin Yang
Journal:  Hum Vaccin Immunother       Date:  2022-04-18       Impact factor: 4.526

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.